Peer-Reviewed Publication
Pediatr Blood Cancer2026;73(7):e70326.July 1, 2026Journal Article
Evaluating the Utility of Paired Tumor and Germline Targeted DNA Sequencing for Pediatric Oncology Patients: A Single Institution Report.
Natalie Waligorski1, Rebecca Ronsley1,2,3, Shannon M Stasi4, Jeffrey Stevens1, Erin R Rudzinski5, Christina M Lockwood4,6, Sarah E S Leary1,2,3, Bonnie L Cole2,4,7, Michelle A Ting1,8, Vera Paulson4,6
1Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.
2Ben Towne Center for Childhood Cancer Research and Blood Disorders, Seattle Children's Research Institute, Seattle, Washington, USA.
3Fred Hutchinson Cancer Center, Seattle, Washington, USA.
4Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
5Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
6Genetics and Solid Tumors Laboratory, Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington, USA.
7Department of Laboratories, Seattle Children's Hospital, Seattle, Washington, USA.
8Tempus AI Inc., Chicago, Illinois, USA.
Abstract
OBJECTIVE: To evaluate the diagnostic yield and utility of universal paired tumor-normal multigene panel sequencing in newly diagnosed pediatric solid and central nervous system (CNS) tumor patients and to compare the detection of germline pathogenic/likely pathogenic variants (PV/LPVs) against established clinical referral criteria for cancer predisposition assessment.
METHODS: From May 2021 to…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans